Oncolytics Biotech, Inc. (USA)  

(Public, NASDAQ:ONCY)   Watch this stock  
Find more results for oncy
1.59
-0.01 (-0.62%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.57 - 1.67
52 week 1.40 - 3.50
Open 1.61
Vol / Avg. 199,427.00/538,148.00
Mkt cap 134.84M
P/E     -
Div/yield     -
EPS -0.30
Shares 84.80M
Beta 2.00
Inst. own 2%
Apr 8, 2014
ONCOLYTICS BIOTECH INC at Needham Healthcare Conference
Apr 8, 2014
Oncolytics Biotech Clinical Update Conference Call
Mar 13, 2014
Q4 2013 ONCOLYTICS BIOTECH INC Earnings Release
Mar 5, 2014
ONCOLYTICS BIOTECH INC at Cowen Health Care Conference - Webcast
Feb 26, 2014
ONCOLYTICS BIOTECH INC Conference Presentation at 2014 RBC Capital Markets Global Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -68.29% -125.20%
Return on average equity -79.77% -164.19%
Employees 25 -
CDP Score - -

Address

210, 1167 Kensington Crescent, N.W.
CALGARY, AB T2N 1X7
Canada
+1-403-6707377 (Phone)
+1-403-2830858 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Oncolytics Biotech Inc. (Oncolytics) is a development-stage company. The Company is focused on its research and development of REOLYSIN, which is its cancer therapeutic. REOLYSIN is developed from the reovirus. This virus has been demonstrated in tumour cells bearing an activated Ras pathway. Oncolytics is directing a clinical trial program with the focus of developing REOLYSIN as a human cancer therapeutic. The clinical program includes clinical trials, which it sponsors directly along with Third Party Clinical Trials. Third Party Clinical Trials are clinical trials that are being sponsored by other institutions. As of December 31, 2011, the United States National Cancer Institute (NCI), the University of Leeds and the Cancer Therapy & Research Center at the University of Texas Health Center in San Antonio (CTRC) were sponsoring part of its clinical trial program. Oncolytics uses contract toll manufacturers to produce REOLYSIN.

Officers and directors

Bradley G. Thompson Ph.D. Executive Chairman of the Board, President, Chief Executive Officer
Bio & Compensation  - Reuters
Kirk J. Look Chief Financial Officer
Bio & Compensation  - Reuters
Matthew C. Coffey Ph.D. Chief Operating Officer, Director
Bio & Compensation  - Reuters
George M. Gill M.D. Senior Vice President - Clinical and Regulatory Affairs
Bio & Compensation  - Reuters
Alan J Tuchman M.D. Chief Medical Officer, Senior Vice President - Medical and Clinical Affairs
Age: 66
Bio & Compensation  - Reuters
Mary Ann Dillahunty J.D. Vice President - Intellectual Property
Bio & Compensation  - Reuters
Robert B. Schultz Lead Independent Director
Bio & Compensation  - Reuters
Wayne F. Pisano Director
Bio & Compensation  - Reuters
Jim Dinning Independent Director
Age: 60
Bio & Compensation  - Reuters
Edwin Levy Ph.D. Independent Director
Bio & Compensation  - Reuters